Skip to Content

47 Results Found

  • Article
  • Open Access
17 Citations
4,224 Views
13 Pages

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: The Feasibility and Benefits of Applying PERCIST

  • Marianne Vogsen,
  • Jakob Lykke Bülow,
  • Lasse Ljungstrøm,
  • Hjalte Rasmus Oltmann and ,
  • Tural Asgharzadeh Alamdari,
  • Mohammad Naghavi-Behzad,
  • Poul-Erik Braad,
  • Oke Gerke and
  • Malene Grubbe Hildebrandt
  • + 4 authors+ 0 author

Background: We aimed to examine the feasibility and potential benefit of applying PET Response Criteria in Solid Tumors (PERCIST) for response monitoring in metastatic breast cancer (MBC). Further, we introduced the nadir scan as a reference. Methods...

(This article belongs to the Special Issue Advances in Multimodality Molecular Imaging)
  • Article
  • Open Access
10 Citations
3,216 Views
13 Pages

Interrater Agreement and Reliability of PERCIST and Visual Assessment When Using 18F-FDG-PET/CT for Response Monitoring of Metastatic Breast Cancer

  • Jonas S. Sørensen,
  • Mie H. Vilstrup,
  • Jorun Holm,
  • Marianne Vogsen and ,
  • Jakob L. Bülow,
  • Lasse Ljungstrøm,
  • Poul-Erik Braad,
  • Oke Gerke and
  • Malene G. Hildebrandt
  • + 4 authors+ 0 author

24 November 2020

Response evaluation at regular intervals is indicated for treatment of metastatic breast cancer (MBC). FDG-PET/CT has the potential to monitor treatment response accurately. Our purpose was to: (a) compare the interrater agreement and reliability of...

(This article belongs to the Special Issue Planning and Evaluating Agreement and Reliability Studies)
  • Article
  • Open Access
8 Citations
3,159 Views
13 Pages

Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria—Which One Is Most Suitable?

  • Gundula Rendl,
  • Gregor Schweighofer-Zwink,
  • Stefan Sorko,
  • Hans-Jürgen Gallowitsch and ,
  • Wolfgang Hitzl,
  • Diana Reisinger and
  • Christian Pirich
  • + 2 authors+ 0 author

7 April 2022

Background: We aimed to compare the established metabolic response criteria PERCIST and EORTC for their applicability and predictive value in terms of clinical response assessment early after the initiation of lenvatinib therapy in patients with meta...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
4 Citations
1,469 Views
7 Pages

Quantitative Comparison of Prone and Supine PERCIST Measurements in Breast Cancer

  • Jennifer G. Whisenant,
  • Jason M. Williams,
  • Hakmook Kang,
  • Lori R. Arlinghaus and ,
  • Richard G. Abramson,
  • Vandana G. Abramson,
  • Kareem Fakhoury,
  • A. Bapsi Chakravarthy and
  • Thomas E. Yankeelov
  • + 4 authors+ 0 author

1 June 2020

Positron emission tomography (PET) is typically performed in the supine position. However, breast magnetic resonance imaging (MRI) is performed in prone, as this improves visibility of deep breast tissues. With the emergence of hybrid scanners that i...

  • Review
  • Open Access
14 Citations
5,448 Views
14 Pages

FDG-PET/CT Versus Contrast-Enhanced CT for Response Evaluation in Metastatic Breast Cancer: A Systematic Review

  • Fredrik Helland,
  • Martine Hallin Henriksen,
  • Oke Gerke,
  • Marianne Vogsen and ,
  • Poul Flemming Høilund-Carlsen and
  • Malene Grubbe Hildebrandt
  • + 1 author+ 0 author

18F-fluorodeoxyglucose positron emission tomography with integrated computed tomography (FDG-PET/CT) and contrast-enhanced computed tomography (CT) can be used for response evaluation in metastatic breast cancer (MBC). In this study, we aimed to revi...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Perspective
  • Open Access
13 Citations
8,422 Views
13 Pages

FDG-PET/CT for Response Monitoring in Metastatic Breast Cancer: Today, Tomorrow, and Beyond

  • Malene Grubbe Hildebrandt,
  • Jeppe Faurholdt Lauridsen,
  • Marianne Vogsen,
  • Jorun Holm and ,
  • Mie Holm Vilstrup,
  • Poul-Erik Braad,
  • Oke Gerke,
  • Mads Thomassen,
  • Marianne Ewertz and
  • The Centre for Personalized Response Monitoring in Oncology (PREMIO)
  • + 6 authors+ 1 author

15 August 2019

While current international guidelines include imaging of the target lesion for response monitoring in metastatic breast cancer, they do not provide specific recommendations for choice of imaging modality or response criteria. This is important as cl...

(This article belongs to the Special Issue Role of Medical Imaging in Cancers)
  • Article
  • Open Access
3 Citations
2,478 Views
15 Pages

Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients

  • Marc Bertaux,
  • Caroline Luo,
  • Camelia Radulescu,
  • Philippe Beuzeboc and ,
  • Cecile Landais,
  • Pauline Touche,
  • Christine Abraham,
  • Marie Homo Seban,
  • Eve Camps and
  • Sabrina Khedairia
  • + 10 authors+ 5 authors

Background/Objectives: Immunotherapy is an essential part of metastatic bladder cancer treatment. Our main objective was to study the prognostic value of FDG-PET/CT in early assessment of response to Pembrolizumab in metastatic bladder cancers using...

(This article belongs to the Special Issue The Medical Applications of Novel PET Radiopharmaceuticals)
  • Review
  • Open Access
5 Citations
2,816 Views
24 Pages

The Role of 18F-FDG PET/CT in Monitoring Immunotherapy Response in Non-Small Cell Lung Cancer: Current Evidence and Challenges: A Narrative Review

  • Roxana Mladin,
  • Cristian Oancea,
  • Emil Robert Stoicescu,
  • Agneta Maria Pusztai and ,
  • Amalia Constantinescu,
  • Emanuel Poplicean and
  • Diana Manolescu
  • + 2 authors+ 0 author

30 October 2025

Background/Objectives: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have transformed treatment paradigms, but assessing response remains challenging due to atypi...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Article
  • Open Access
13 Citations
2,565 Views
21 Pages

Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial

  • Annette M. Lim,
  • Benjamin Baker,
  • Peter Lion,
  • Christopher M. Angel and ,
  • Jennifer Simmons,
  • Bryce Jackson,
  • Matthew Magarey,
  • Angela Webb,
  • Kevin Nguyen and
  • Danny Rischin
  • + 12 authors+ 7 authors

21 May 2025

Background: A previous published Phase 2 trial using 2–4 doses of neoadjuvant cemiplimab in stage II–IV resectable cutaneous squamous cell carcinoma (CSCC) demonstrated that a complete pathological (pCR) rate of 51% and major pathological...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Article
  • Open Access
1 Citations
2,133 Views
13 Pages

Radioembolization-Induced Changes in Hepatic [18F]FDG Metabolism in Non-Tumorous Liver Parenchyma

  • Manon N. Braat,
  • Caren van Roekel,
  • Marnix G. Lam and
  • Arthur J. Braat

17 October 2022

Background: [18F]FDG-PET/CT is increasingly used for response assessments after oncologic treatment. The known response criteria for [18F]FDG-PET/CT use healthy liver parenchyma as the reference standard. However, the [18F]FDG liver metabolism result...

(This article belongs to the Topic F-18 FDG PET/CT Imaging)
  • Article
  • Open Access
2 Citations
1,340 Views
18 Pages

Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1–2 Breast Cancer: An Internally Validated PET/CT-Integrated Nomogram

  • Mustafa Berkeşoğlu,
  • Gözde Arslan,
  • Ferah Tuncel,
  • Cumhur Özcan and ,
  • Zehra Pınar Koç,
  • Pınar Pelin Özcan,
  • Erkan Güler,
  • Sami Benli,
  • Yüksel Balcı and
  • Kadir Eser
  • + 5 authors+ 0 author

28 November 2025

We aimed to develop and internally validate a nomogram to estimate axillary pathological complete response (pCR, ypN0) after neoadjuvant systemic therapy (NAST) in clinically node-positive (cN1–2) breast cancer. In a single-center retrospective...

  • Article
  • Open Access
11 Citations
3,269 Views
15 Pages

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT

  • Kazuhiro Kitajima,
  • Mitsunari Maruyama,
  • Hiroyuki Yokoyama,
  • Toshiyuki Minami and ,
  • Takashi Yokoi,
  • Akifumi Nakamura,
  • Masaki Hashimoto,
  • Nobuyuki Kondo,
  • Kozo Kuribayashi and
  • Koichiro Yamakado
  • + 7 authors+ 2 authors

4 March 2021

Background: To compare three FDG-PET criteria (EORTC, PERCIST, imPERCIST) with CT criteria (combined modified RECIST and RECIST 1.1) for response evaluation and prognosis prediction in patients with recurrent MPM treated with ICI monotherapy. Methods...

(This article belongs to the Special Issue Malignant Mesothelioma)
  • Article
  • Open Access
9 Citations
2,973 Views
14 Pages

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors

  • Alexia Rivas,
  • Julie Delyon,
  • Antoine Martineau,
  • Estelle Blanc and ,
  • Clara Allayous,
  • Laetitia Da Meda,
  • Pascal Merlet,
  • Céleste Lebbé,
  • Barouyr Baroudjian and
  • Laetitia Vercellino
  • + 5 authors+ 0 author

29 June 2022

Background: Immune checkpoint inhibitors (ICI) are currently the first-line treatment for patients with metastatic melanoma. We investigated the value of positron emission tomography (PET) response criteria to assess the therapeutic response to first...

(This article belongs to the Collection Targeted Therapies and Immunotherapies in Metastatic Melanoma)
  • Article
  • Open Access
5 Citations
3,202 Views
13 Pages

Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer

  • Michael Beck,
  • Sabine Semrau,
  • Marlen Haderlein,
  • Antoniu-Oreste Gostian and ,
  • Julius Hartwich,
  • Sarina Müller,
  • Annett Kallies,
  • Carol-Immanuel Geppert,
  • Miriam Schonath and
  • Markus Hecht
  • + 15 authors+ 10 authors

30 September 2022

Background: In head and neck cancer patients, parameters of metabolic and morphologic response of the tumor to single-cycle induction chemotherapy (IC) with docetaxel, cis- or carboplatin are used to decide the further course of treatment. This study...

(This article belongs to the Section Cancer Immunology and Immunotherapy)
  • Concept Paper
  • Open Access
48 Citations
14,577 Views
17 Pages

In this era of precision oncology, there has been an exponential growth in the armamentarium of genomically targeted therapies and immunotherapies. Evaluating early responses to precision therapy is essential for “go” versus “no go” decisions for the...

(This article belongs to the Special Issue Imaging of Early Response in Cancer Management)
  • Editorial
  • Open Access
8 Citations
7,394 Views
5 Pages

A Promising Future for Prostate Cancer Diagnostics

  • Stephen J. Assinder and
  • Vanitha Bhoopalan

It has been estimated that globally there is a death attributable to prostate cancer every four minutes. As life expectancy in all world regions increases, so too incidence of this disease of the ageing male will increase. For many men diagnosis occu...

(This article belongs to the Special Issue Prostate Cancer Diagnosis)
  • Review
  • Open Access
11 Citations
3,344 Views
22 Pages

Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology

  • Maria Isabella Donegani,
  • Giulia Ferrarazzo,
  • Stefano Marra,
  • Alberto Miceli and ,
  • Stefano Raffa,
  • Matteo Bauckneht and
  • Silvia Morbelli
  • + 2 authors+ 0 author

24 July 2020

2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patien...

  • Review
  • Open Access
2 Citations
2,960 Views
18 Pages

21 August 2024

Introduction: There is growing interest in the development and application of standardized imaging criteria (SIC), to minimize variability and improve the reproducibility of image interpretation in head and neck squamous cell carcinoma (HNSCC). Metho...

(This article belongs to the Special Issue Head and Neck Cancer: Advanced PET/CT and MRI Imaging with a Focus on Current and Emerging Molecular Theranostics)
  • Article
  • Open Access
29 Citations
4,130 Views
14 Pages

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy

  • Friederike Völter,
  • Lena Mittlmeier,
  • Astrid Gosewisch,
  • Julia Brosch-Lenz and ,
  • Franz Josef Gildehaus,
  • Mathias Johannes Zacherl,
  • Leonie Beyer,
  • Christian G. Stief,
  • Adrien Holzgreve and
  • Harun Ilhan
  • + 10 authors+ 5 authors

Background: Dosimetry can tailor prostate-specific membrane-antigen-targeted radioligand therapy (PSMA-RLT) for metastatic castration-resistant prostate cancer (mCRPC). However, whole-body tumor dosimetry is challenging in patients with a high tumor...

(This article belongs to the Special Issue Novel Theranostic Agents)
  • Article
  • Open Access
11 Citations
3,326 Views
9 Pages

Utility of Integrated PET/MRI for the Primary Diagnostic Work-Up of Patients with Ewing Sarcoma: Preliminary Results

  • Michal Chodyla,
  • Francesco Barbato,
  • Uta Dirksen,
  • Julian Kirchner and ,
  • Benedikt M. Schaarschmidt,
  • Bernd Schweiger,
  • Michael Forsting,
  • Ken Herrmann,
  • Lale Umutlu and
  • Johannes Grueneisen
  • + 5 authors+ 0 author

21 September 2022

Background: This study was conducted to evaluate the clinical applicability of integrated PET/MRI for staging and monitoring the effectiveness of neoadjuvant chemotherapy in Ewing sarcoma patients. Methods: A total of 11 juvenile patients with confir...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Review
  • Open Access
12 Citations
5,516 Views
19 Pages

Imaging Assessment of Tumor Response in the Era of Immunotherapy

  • Jun Nakata,
  • Kayako Isohashi,
  • Yoshihiro Oka,
  • Hiroko Nakajima and ,
  • Soyoko Morimoto,
  • Fumihiro Fujiki,
  • Yusuke Oji,
  • Akihiro Tsuboi,
  • Atsushi Kumanogoh and
  • Haruo Sugiyama
  • + 7 authors+ 2 authors

Assessment of tumor response during treatment is one of the most important purposes of imaging. Before the appearance of immunotherapy, response evaluation criteria in solid tumors (RECIST) and positron emission tomography response criteria in solid...

(This article belongs to the Special Issue Radiomics in Oncology)
  • Article
  • Open Access
28 Citations
3,975 Views
13 Pages

18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib

  • Freba Ahmaddy,
  • Caroline Burgard,
  • Leonie Beyer,
  • Viktoria Florentine Koehler and ,
  • Peter Bartenstein,
  • Matthias P. Fabritius,
  • Thomas Geyer,
  • Vera Wenter,
  • Harun Ilhan and
  • Andrei Todica
  • + 6 authors+ 1 author

16 January 2021

Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[18F...

(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Thyroid Carcinoma)
  • Article
  • Open Access
8 Citations
3,873 Views
12 Pages

Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma

  • Hye Lim Park,
  • Eun Ji Han,
  • Joo Hyun O,
  • Byung-Ock Choi and ,
  • Gyeongsin Park,
  • Seung-Eun Jung,
  • Seung-Ah Yahng,
  • Ki-Seong Eom,
  • Seok-Goo Cho and
  • on behalf of Catholic University Lymphoma Group
  • + 5 authors+ 0 author

24 November 2020

Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) after one cycle of standard chemotherapy in patients with diffuse large B cell lymphoma (DLBCL) was assessed. Prospectively enrolled 51 patients had four...

(This article belongs to the Special Issue Positron Emission Tomography (PET) Imaging for Therapy Monitoring)
  • Review
  • Open Access
5 Citations
4,334 Views
14 Pages

[18F]FDG PET/CT Integration in Evaluating Immunotherapy for Lung Cancer: A Clinician’s Practical Approach

  • Juliette Brezun,
  • Nicolas Aide,
  • Evelyne Peroux,
  • Jean-Laurent Lamboley and ,
  • Fabrice Gutman,
  • David Lussato and
  • Carole Helissey
  • + 2 authors+ 0 author

23 September 2024

The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment paradigm of lung cancer, resulting in notable enhancements in patient survival. Nevertheless, evaluating treatment response in patients undergoing immunotherapy poses...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Review
  • Open Access
32 Citations
7,099 Views
22 Pages

3 November 2021

Immunotherapy with checkpoint inhibitors has prompted a major change not only in cancer treatment but also in medical imaging. In parallel with the implementation of new drugs modulating the immune system, new response criteria have been developed, a...

(This article belongs to the Special Issue Cancer Management in the Era of Immunotherapy)
  • Article
  • Open Access
2 Citations
2,182 Views
10 Pages

27 August 2024

Background: Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) is a firmly established tool in oncology and is gaining importance in dermato-oncology. However, its use in advanced basal cell carcinoma (BCC...

(This article belongs to the Section Nuclear Medicine & Radiology)
  • Article
  • Open Access
35 Citations
4,615 Views
14 Pages

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223

  • Matteo Bauckneht,
  • Selene Capitanio,
  • Maria Isabella Donegani,
  • Elisa Zanardi and ,
  • Alberto Miceli,
  • Roberto Murialdo,
  • Stefano Raffa,
  • Laura Tomasello,
  • Martina Vitti and
  • Silvia Morbelli
  • + 13 authors+ 8 authors

20 December 2019

Radium-223 dichloride (Ra223) represents the unique bone-directed treatment option that shows an improvement in overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC). However, there is an urgent need for the identification of...

(This article belongs to the Special Issue Role of Medical Imaging in Cancers)
  • Article
  • Open Access
8 Citations
4,153 Views
14 Pages

18F-Fluorodeoxyglucose PET/CT for Early Prediction of Outcomes in Patients with Advanced Lung Adenocarcinomas and EGFR Mutations Treated with First-Line EGFR-TKIs

  • Yu-Erh Huang,
  • Ying-Huang Tsai,
  • Yu-Jie Huang,
  • Jr-Hau Lung and ,
  • Kuo-Wei Ho,
  • Tzu-Chen Yen,
  • Sheng-Chieh Chan,
  • Shu-Tian Chen,
  • Ming-Feng Tsai and
  • Ming-Szu Hung
  • + 5 authors+ 0 author

15 March 2022

This study aims to investigate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in early prediction of response and survival following epithelial growth factor receptor (EGFR)–tyrosine kinase...

(This article belongs to the Collection Imaging Biomarker in Oncology)
  • Article
  • Open Access
21 Citations
3,695 Views
16 Pages

Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy

  • Olena Tankyevych,
  • Flora Trousset,
  • Claire Latappy,
  • Moran Berraho and ,
  • Julien Dutilh,
  • Jean Pierre Tasu,
  • Corinne Lamour and
  • Catherine Cheze Le Rest
  • + 3 authors+ 0 author

30 November 2022

Purpose: We aimed to assess the ability of radiomics features extracted from baseline (PET/CT0) and follow-up PET/CT scans, as well as their evolution (delta-radiomics), to predict clinical outcome (durable clinical benefit (DCB), progression, respon...

(This article belongs to the Special Issue PET and MRI Radiomics in Cancer Predictive Modeling)
  • Article
  • Open Access
41 Citations
10,128 Views
15 Pages

13 October 2015

The purpose of this study was to evaluate the outcome after Radium-223-dichloride (223RaCl2) treatment of patients with skeletal metastases of castration resistant prostate cancer using whole-body 18F-Fluoride PET/CT. Sodium 18F-fluoride [18F]-NaF PE...

(This article belongs to the Special Issue Prostate Cancer Diagnosis)
  • Review
  • Open Access
13 Citations
5,247 Views
10 Pages

Immuno-Imaging (PET/SPECT)–Quo Vadis?

  • Carsten S. Kramer and
  • Antonia Dimitrakopoulou-Strauss

The use of immunotherapy has revolutionized the treatment regimen of certain cancer types, but response assessment has become a difficult task with conventional methods such as CT/MRT or FDG PET-CT and the classical response criteria such as RECIST o...

  • Article
  • Open Access
26 Citations
5,217 Views
11 Pages

Electrochemotherapy Is Effective in the Treatment of Bone Metastases

  • Laura Campanacci,
  • Luca Cevolani,
  • Francesca De Terlizzi,
  • Laura Saenz and ,
  • Nikolin Alì,
  • Giuseppe Bianchi and
  • Davide Maria Donati
  • + 2 authors+ 0 author

4 March 2022

Bone metastases induce pain, risk of fracture, and neural compression, and reduced mobility and quality of life. Electrochemotherapy (ECT) is a minimally invasive local treatment based on a high-voltage electric pulse combined with an anticancer drug...

(This article belongs to the Special Issue Treatment of Bone Metastasis)
  • Article
  • Open Access
12 Citations
3,963 Views
12 Pages

Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC)

  • Elisa Lodi Rizzini,
  • Andrea Repaci,
  • Elena Tabacchi,
  • Lucia Zanoni and ,
  • Valentina Vicennati,
  • Ottavio Cavicchi,
  • Uberto Pagotto,
  • Alessio Giuseppe Morganti,
  • Stefano Fanti and
  • Fabio Monari
  • + 5 authors+ 0 author

Background: As reported in the literature, [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT) provides useful qualitative and semi-quantitative data for the prognosis of advanced differentiated thyroid cancer...

(This article belongs to the Special Issue Image-Based Diagnostics and Radiometabolic Therapy of Differentiated Thyroid Cancer)
  • Interesting Images
  • Open Access
1 Citations
3,825 Views
3 Pages

18F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab

  • Romain-David Seban,
  • Anne Donnadieu,
  • Gabrielle Journo,
  • Francois-Clement Bidard and ,
  • Capucine Richard,
  • Roman Rouzier and
  • Laurence Champion
  • + 2 authors+ 0 author

Dostarlimab is an immune checkpoint inhibitor (ICI) targeting the Programmed-Death-1 (PD-1) co-receptor, recently approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) as a novel therapy for recurrent or advanced...

(This article belongs to the Special Issue Imaging of Gynecological Disease)
  • Article
  • Open Access
26 Citations
3,419 Views
16 Pages

Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell Lymphoma: Is There a Superior Method?

  • Florian Eude,
  • Mathieu Nessim Toledano,
  • Pierre Vera,
  • Hervé Tilly and ,
  • Sorina-Dana Mihailescu and
  • Stéphanie Becker
  • + 1 author+ 0 author

26 January 2021

The metabolic tumour volume (MTV) is an independent prognostic indicator in diffuse large B-cell lymphoma (DLBCL). However, its measurement is not standardised and is subject to wide variations depending on the method used. This study aimed to compar...

(This article belongs to the Special Issue Metabolic Volume Measurements)
  • Review
  • Open Access
411 Views
23 Pages

Personalized Management of Erdheim–Chester Disease: The Pivotal Role of Molecular and Cross-Sectional Imaging from Staging to Targeted Therapy Monitoring

  • Stefano Piscone,
  • Luca Pio Stoppino,
  • Martina Matera,
  • Benedetta Di Millo and ,
  • Giorgia Schiraldi,
  • Paola Milillo,
  • Roberta Vinci and
  • Luca Macarini
  • + 3 authors+ 0 author

29 September 2026

Erdheim–Chester disease (ECD) is a rare, clonal non-Langerhans cell histiocytic neoplasm driven by activating mutations in the mitogen-activated protein kinase (MAPK) pathway, most notably the BRAF-V600E mutation. The discovery of these molecul...

(This article belongs to the Special Issue Molecular Imaging Application in Personalized Diagnosis and Therapy)
  • Article
  • Open Access
30 Citations
4,218 Views
14 Pages

Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy

  • Fadi Khreish,
  • Mona Wiessner,
  • Florian Rosar,
  • Zaidoon Ghazal and ,
  • Amir Sabet,
  • Stephan Maus,
  • Johannes Linxweiler,
  • Mark Bartholomä and
  • Samer Ezziddin
  • + 4 authors+ 0 author

26 July 2021

At present, little is known about the molecular imaging-based response assessment of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lutetium (177Lu-PSMA-617 RLT) in metastatic castration-resistant prostate cancer (mCRP...

(This article belongs to the Special Issue Prostate Cancer: From Models to Molecular Mechanisms and Precision Medicine)
  • Article
  • Open Access
15 Citations
2,859 Views
11 Pages

Rationale: To formally determine the repeatability of Ga-68 PSMA lesion uptake in both relapsing and metastatic tumor. In addition, it was hypothesized that the BPL algorithm Q. Clear has the ability to lower SUV signal variability in the small lesio...

(This article belongs to the Special Issue Quantitative PET and SPECT)
  • Article
  • Open Access
6 Citations
2,455 Views
17 Pages

Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation

  • Serena Janho dit Hreich,
  • Olivier Humbert,
  • Tanguy Pacé-Loscos,
  • Renaud Schiappa and ,
  • Thierry Juhel,
  • Marius Ilié,
  • Victoria Ferrari,
  • Jonathan Benzaquen,
  • Paul Hofman and
  • Valérie Vouret-Craviari
  • + 5 authors+ 0 author

14 June 2024

The aim of this study was to assess the potential value of circulating active and inactive IL-18 levels in distinguishing pseudo and true tumor progression among NSCLC patients receiving immune checkpoint inhibitor treatments (ICIs). Methods: This an...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
20 Citations
4,153 Views
12 Pages

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?

  • Philipp E. Hartrampf,
  • Marieke Heinrich,
  • Anna Katharina Seitz,
  • Joachim Brumberg and ,
  • Ioannis Sokolakis,
  • Charis Kalogirou,
  • Andreas Schirbel,
  • Hubert Kübler,
  • Andreas K. Buck and
  • Markus Krebs
  • + 6 authors+ 1 author

(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is uncl...

(This article belongs to the Section Nuclear Medicine & Radiology)
  • Article
  • Open Access
2 Citations
3,206 Views
13 Pages

Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer

  • Riccardo Ray Colciago,
  • Chiara Chissotti,
  • Federica Ferrario,
  • Maria Belmonte and ,
  • Giorgio Purrello,
  • Valeria Faccenda,
  • Denis Panizza,
  • Stefania Canova,
  • Gaia Passarella and
  • Stefano Arcangeli
  • + 6 authors+ 1 author

2 November 2024

We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC. A retrospective analysis was conducted on NSCLC patien...

(This article belongs to the Special Issue Hype or Hope—Combination Therapies for Lung Cancer)
  • Article
  • Open Access
317 Views
15 Pages

Association of Complete Metabolic Response on Post-Neoadjuvant 18F-FDG PET/CT with Complete Cytoreduction in Advanced High-Grade Serous Tubo-Ovarian Carcinoma: A Retrospective Single-Center Cohort Study

  • Basak Ozge Kayan,
  • Ipek Ozturk,
  • Yahya Ozgun Oner,
  • Burcu Esen Akkas and ,
  • Meryem Kaya,
  • Nilufer Bulut,
  • Semra Altinay,
  • Gozde Sahin,
  • Isik Sozen and
  • Ilkbal Temel Yuksel
  • + 5 authors+ 0 author

29 September 2026

Background/Objectives: To evaluate whether complete metabolic response (CMR) on 18F-FDG PET/CT after neoadjuvant chemotherapy (NACT) is associated with complete cytoreduction at interval debulking surgery (IDS), progression-free survival (PFS), and o...

(This article belongs to the Section Medical Imaging and Theranostics)
  • Article
  • Open Access
2,641 Views
18 Pages

Radiomics-Based Prediction of Treatment Response to TRuC-T Cell Therapy in Patients with Mesothelioma: A Pilot Study

  • Hubert Beaumont,
  • Antoine Iannessi,
  • Alexandre Thinnes,
  • Sebastien Jacques and
  • Alfonso Quintás-Cardama

29 January 2025

Background/Objectives: T cell receptor fusion constructs (TRuCs), a next generation engineered T cell therapy, hold great promise. To accelerate the clinical development of these therapies, improving patient selection is a crucial pathway forward. Me...

(This article belongs to the Special Issue Biomarkers and Targeted Therapy in Malignant Pleural Mesothelioma)
  • Article
  • Open Access
1,207 Views
13 Pages

Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study

  • Priscilla Guglielmo,
  • Carlo Carnaghi,
  • Alexia Francesca Bertuzzi,
  • Alice Laffi and ,
  • Sara Damiani,
  • Ugo Carlo Riva,
  • Michela Olivieri,
  • Manuela Marenco and
  • Laura Evangelista
  • + 4 authors+ 0 author

16 April 2026

Background/Objectives: Assessing treatment response in neuroendocrine tumors (NETs) remains challenging. The multifactorial mechanism of action of peptide receptor radionuclide therapy (PRRT) further complicates response evaluation, particularly in t...

(This article belongs to the Special Issue Hybrid Molecular Imaging Approaches in Cancer: PET/CT, PET/MRI, and Beyond)
  • Article
  • Open Access
640 Views
26 Pages

Group-Aware Registration for Lesion-Level Quantitative Motion Correction in Respiratory-Gated PET/CT Biomedical Imaging

  • Hui Zhou,
  • Longxi He,
  • Yangsheng Hu,
  • Zhouyuan Qin and ,
  • Feng Wang and
  • Jianfeng He
  • + 1 author+ 0 author

17 July 2026

Respiratory-gated PET/CT generates phase-resolved biomedical imaging data, but respiratory motion can cause spatial mismatch and lesion-level quantitative instability, especially for small thoracoabdominal lesions. This study proposes SCAR-Net, a Sim...

(This article belongs to the Special Issue Advanced Biomedical Imaging and Signal Processing)
  • Article
  • Open Access
1 Citations
1,353 Views
14 Pages

Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

  • Vali Aliyev,
  • Ali Kaan Güren,
  • Murad Guliyev,
  • Zeliha Birsin and ,
  • Murat Günaltılı,
  • Mehmet Cem Fidan,
  • Emir Çerme,
  • Hamza Abbasov,
  • Selin Cebeci and
  • Nebi Serkan Demirci
  • + 10 authors+ 5 authors

5 March 2026

Background and objectives: Early biomarkers that can reliably predict treatment outcomes during CDK4/6 inhibitor therapy remain an unmet clinical need in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/H...

(This article belongs to the Special Issue Advances in Cancer Imaging, Radiomics, and Radiotherapy)
  • Article
  • Open Access
24 Citations
4,009 Views
16 Pages

Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T

  • Lena M. Unterrainer,
  • Leonie Beyer,
  • Mathias J. Zacherl,
  • Franz J. Gildehaus and ,
  • Andrei Todica,
  • Sophie C. Kunte,
  • Adrien Holzgreve,
  • Gabriel T. Sheikh,
  • Annika Herlemann and
  • Marcus Unterrainer
  • + 16 authors+ 11 authors

Background: PSMA-based alpha therapy using 225Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume...

(This article belongs to the Special Issue New Generation Imaging in Oncology 2.0)